Similar to our results, Dosset et al. and Guan et al. found that the addition of FOLFOX (5-Fluorouracil plus Oxa) to anti-PD-1 therapy induces the activation of the presence of tumor antigen-specific PD-1+ CD8+ T cells and the expression of PD-L1 of tumor cells in tumors, and promotes tumor regression more than FOLFOX or anti-PD-1 alone in CRC tumor-bearing mice [19,43]. The gene discussed is CD274; the disease is colorectal carcinoma.